Related Experiment Video

Updated: Jan 22, 2026

Author Spotlight: Expanding the Scope of Multiplex Immunoassays for Lyme Borreliosis Diagnostics and Pathogen Research
05:25

Author Spotlight: Expanding the Scope of Multiplex Immunoassays for Lyme Borreliosis Diagnostics and Pathogen Research

Published on: July 14, 2023

1.9K

Interleukin-35: A Serological Biomarker for Patients with Polymyositis/Dermatomyositis

Qinglai Jiang1, Yuxuan Li1, Liping Xia1

  • 1Department of Rheumatology and Immunology, the First Affiliated Hospital of China Medical University, Shenyang, P.R. China.

Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research
|July 6, 2019
PubMed

Insights

Interleukin (IL)-35, a key immune modulator, is elevated in polymyositis/dermatomyositis (PM/DM) patients. Higher IL-35 levels correlate with disease activity and interstitial lung disease, suggesting an anti-inflammatory role.

Area of Science:

  • Immunology
  • Rheumatology
  • Molecular Biology

Background:

  • Interleukin (IL)-35 is recognized as a crucial regulator of immune responses.
  • Polymyositis/dermatomyositis (PM/DM) are inflammatory myopathies with complex immune system involvement.

Purpose of the Study:

  • To investigate the role and significance of IL-35 in the pathogenesis of polymyositis/dermatomyositis (PM/DM).
  • To assess IL-35 serum levels in PM/DM patients compared to healthy controls and correlate findings with clinical features.

Main Methods:

  • Recruitment of 95 PM/DM patients and 30 healthy controls (HCs).
  • Isolation of peripheral blood mononuclear cells (PBMCs).
  • Quantification of serum IL-35, IL-17, and tumor necrosis factor-alpha (TNF-α) using enzyme-linked immunosorbent assay (ELISA).

Main Results:

  • PM/DM patients exhibited significantly higher serum IL-35 levels than HCs.
  • Elevated IL-35 levels correlated with disease activity, muscle damage, and interstitial lung disease (ILD) in PM/DM.
  • In vitro, IL-35 suppressed lipopolysaccharide-induced IL-17 and TNF-α production in PM/DM patient PBMCs.

Conclusions:

  • Serum IL-35 may serve as a valuable biomarker for disease activity and an indicator of ILD in PM/DM.
  • IL-35 appears to exert an anti-inflammatory effect within the context of PM/DM.
  • Further research into IL-35's therapeutic potential in PM/DM is warranted.
Keywords:
disease activityinterleukin-35interstitial lung diseasepolymyositis/dermatomyositis

More Related Videos

Biomarkers in an Animal Model for Revealing Neural, Hematologic, and Behavioral Correlates of PTSD08:29

Biomarkers in an Animal Model for Revealing Neural, Hematologic, and Behavioral Correlates of PTSD

Published on: October 10, 2012

16.7K
Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

3.3K

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
816
Patient-centered Care01:13

Patient-centered Care

Patient-centered care involves delivering care beyond inpatient hospitalization. Reflective practice can enhance a patient-centered approach. Reflective practice is a process of reasoning that considers all aspects of the present situation, including practicalities, learning from personal practice, and consideration of patient needs. Patients appreciate care decisions made while considering their input. Involving the patient in their care provides the patient with a sense of contribution rather...
2.9K
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
235
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
229
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
269
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
198